Introduction
The subjective effects of antipsychotic medication are increasingly recognized as important determinants of well-being and compliance. This raises the question as to whether existing scales for measuring these subjective effects are covering the entire spectrum of experiences that patients attribute to these drugs.
The subjective effects of antipsychotic medication have been associated with medication (non)-compliance (van Putten et al., 1981; Weiden et al., 1989; Naber et al., 1994; Agarwal et al., 1998; Cabeza et al., 2000) , therapeutic effect (van Putten and May, 1978; Hogan et al., 1985; Hogan and Awad, 1992) , quality of life (Naber, 1998) , objective side-effects (Hogan and Awad, 1992) and suicidal behavior (Awad et al., 1995) . Subjective response has not been studied as thoroughly as objective aspects like efficacy and motor side-effects. This may be partly due to the lack of a generally accepted concept. Existing concepts include mostly negative experiences and neglect positive ones (Awad, 1993; Naber, 1995) .
One of the first studies on the subjective response to antipsychotic medication was done by van Putten and May (1978) . Their hypothesis was that the early subjective response predicted eventual treatment outcome. They measured the subjective response with four questions: (i) how does the medication agree with you; (ii) did it make you feel calmer; (iii) did it affect your thinking; and (iv) do you think this is the right medicine for you? The subjective response was graded on a euphoric-dysphoric continuum. In general an early positive subjective response predicted a positive change in clinical status. Van Putten and May pointed out that the question 'How does the medication agree with you?' is very important even at the beginning of the treatment. Their study was a very limited one, because of the non-specific questions. Hogan et al. (1985) developed an instrument for measuring the subjective response by collecting statements made by schizophrenic patients about the medication they received.
These statements reflected both subjective feelings and attitudes. Thirty items were found to discriminate significantly between compliant and non-compliant patients. A factor analysis generated seven factors: subjective positive, subjective negative, health/illness, physician, control, prevention and harm. The positive subjective factor encompasses eight experiences expressing the positive feelings which the patient attributes to antipsychotic medication. The negative subjective factor consists of six experiences expressing the dysphoric feelings attributed to the antipsychotic medication. Unfortunately, the resulting instrument, the Drug Attitude Inventory-10 (DAI-10), contaminates subjective response with attitude towards medication and knowledge about relapse prevention. Furthermore, the statements were not collected in a structured way but were recorded by the psychiatrist involved in the treatment of the patients. Naber et al. (1994) also published an instrument for measuring the subjective aspects of medication treatment, the Subjective Well-being on Neuroleptics (SWN). They selected items based on literature and clinical experience. The original 54 statements were reduced to 38 after an examination of item-scale correlations, variance and subjective importance.
There are subscales for measuring emotional regulation, self-control, mental functioning, social integration, and physical functioning. However, inspection of the scale shows that it measures quality of life rather then experiences attributed to antipsychotic medication. In order to improve the utility of the SWN for clinical settings, a short form was developed.
Items were removed until every subscale consisted of four items (2001).
The existing scales have a number of shortcomings. Their main disadvantage is that they have been composed from a 'doctor's perspective' and do not represent the 'patient's' point of view. Moreover, they neglect the possibility that different patients may value the same medication effects positively or negatively. Diamond (1985) , for instance, published some cases to demonstrate the importance of the subjective and objective, negative and positive effects of antipsychotic medication. He concludes that there must be a balance between these different approaches.
We carried out an exploratory study that collects positive as well as negative experiences and that is based on a broad sample of a variety of experiences which patients attribute to their use of antipsychotic medication. Depending on the result, we consider the development of a more comprehensive scale.
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Method
Subjects
Inclusion criteria were a diagnosis within the schizophrenia spectrum (schizophrenia or schizoaffective disorder according to DSM-IV criteria) and treatment with antipsychotic medication for at least 6 weeks. Exclusion criteria were the use of lithium and antidepressive medication. Seventy-seven patients agreed to participate in the study (52 men and 25 women). Their mean age was 33 years (SD=10.5). After obtaining informed consent, the interviews were done by a psychologist (HAW) who was not involved in the treatment of these patients. At inclusion 61% were using atypical antipsychotic medication, 35% were using classical antipsychotics and 4% were using a combination of drugs (Table 1) . Mean total lifetime duration of antipsychotic drug use was 44 months (SD=44.3, range 1.5-320).
Mean duration of current medication was 19 months (SD=19.2, range 1.5-168). Forty-eight per cent of the patients used only antipsychotic medication; 52% of the patients used comedication, mainly benzodiazepines or anticholinergics. Oral antipsychotic medication was used by 91% of the patients and depot medication by 9%. Patients were asked about forgetting or refusal to take their medication as prescribed: 28.6% admitted noncompliance.
Sixty-eight interviews were audiotaped; nine patients felt uncomfortable when the interview was taped and their answers were written down during the interview as expressed by the subject. 
Instruments
Experiences of patients attributed to antipsychotic medication were collected with a semistructured interview, consisting of: (i) a small set of general questions about any
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The spectrum of subjective effects of antipsychotic medication experienced effect, at any time attributed to antipsychotic drugs by the patient; (ii) more structured questions followed, in which patients were prompted in a neutral way to talk about any experience attributed to antipsychotics, whether positively or negatively evaluated, in three domains: psychological, somatic and social; (iii) finally, patients were asked about 50 selected side-effects based on the Udvalg for Kliniske Undersoegelser (UKU; Lingjaerde et al., 1987) and on a publication by Hogan et al. (1983) . In case of a positive response, patients were asked whether they attributed the effect to their antipsychotic medication. Only these answers were included.
The tapes were summarized in transcriptions noting affirmative responses of the patients in their own wording. Nine patients did not agree with audiotaping. Their responses were also summarized. The transcriptions and keywords were added to a database. Next, seven independent mental health professionals categorized these responses on the basis of similarity. Based on these categories, statements were formulated as much as possible in the wording chosen by the patients. The final set included all experiences reported by at least five patients as well as a number of additional experiences which were judged to be of clinical significance.
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Results
Interview data
The first two sections of the interview generated a total of 760 responses: 61% were of a psychological nature, 30% were about somatic effects, and 9% were about effects on social interaction. There were an average of 9.9 responses (SD=5. 'I have gained weight'; I have less need for sex').
Checklist
We obtained prompted responses with a checklist as described, comprising 50 items. A mean of 12.5 (SD=7.3; range 0-28) of these items were confirmed by the patients and attributed to antipsychotic medication. This is somewhat higher than the number of spontaneous responses. Patients who used co-medication did not attribute more responses to the antipsychotic drugs than patients who used antipsychotic medication (t=0.70, ns). The answers replicated responses obtained with the interview, with only one exception. The checklist item 'feeling like a zombie' could not be identified in the interview data. If patients were asked to explain this experience, they described it as a combination of disturbance in emotion and motor effects, both of which are covered by our interview data set.
Categories
An exploratory analysis of the final set revealed a number of domains which could be valued both positively and negatively. Statements could be categorized into two major classes:
psychological effects and somatic effects. Within the psychological class, a subdivision could be made into effects on emotion, cognition and sociability. Within the somatic class, a further division into effects on activation and effects on physiological functions seemed 29
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Compliance
The results show that medication non-compliant patients and compliant patients (according tot selfreport) have different subjective side-effect profiles, but these differences are small.
Compliant patients reported less positively valued decrease of emotion (Mann-Whitney = 320, P =0.04). Some positively valued somatic effects (appetite and weight gain) were only reported by compliant patients (n=4). 
Discussion
We included a broad sample of patients with varying durations of medication usage, using depot and oral prescriptions, comprising classical and atypical drugs. Our approach might have led to an underestimation of negative responses, because patients who discontinued antipsychotic medication were not included in the sample. However, we compared responses of medication non-compliant patients with those of compliant patients and we found that the differences were small and limited to the subjective evaluation of side-effects affecting appetite, weight and (lack of) appreciation of levelling of emotions. Co-medication was not of great influence. We feel confident that we were able to collect a broad and representative range of subjective experiences that patients attribute to their use of various types of antipsychotic medication. We found hardly any significant differences between drugs that are currently being used regarding medication effects. Such differences, however, are likely to be obscured by the fact that patients were asked to report effects they experienced at any time when using antipsychotics, because we aimed at a broad sampling of experiences.
The checklist provided no additional statements, which suggests that our collection represents the variety of experiences quite well. However, patients reported on average more responses with the help of the checklist than spontaneously during the interview.
Any attempt at categorizing these experiences into domains of functioning is inevitably arbitrary to some extent. Nevertheless, a distinction between psychological and somatic effects seems quite natural. Within the first category, there is at least face validity for a distinction between emotional and cognitive effects. Effects on social function, as described by our subjects, clearly refer to their motivation and their capacity for social interaction. We suggest that these experiences refer to a psychological effect on their sociability. Somatic effects are varied, but a large number of these experiences refer to changes of the level of activation. There is a residual category, comprising a variety of effects on physiological functions.
Patients report a large number of positive experiences in the psychological domain, but much less so in the somatic domain. The prime emotion effect is a flattening, which may be valued positively by one patient and negatively by another. Other patients, however, report an increase of emotions. The spectrum of these effects encompasses depression, anxiety, irritability, spontaneity and cheerfulness, reflecting differing extents of emotional downregulation or up-regulation. Cognitive effects attributed to antipsychotics range from a decrease in psychotic symptoms to an increase, and from a worsening of cognitive functions (attention, memory, speed, creativity, control) to an improvement. Effects on sociability point to changes of cognitive efficacy, but also to motivation and interest. Again, these effects range from worsening to improvement. The level of activation may also decrease or increase, and again these effects are positive experiences for one patient and negative ones for another. The effects range from restlessness to tranquillity, and from activity to tiredness, slowness and drowsiness. Finally, many patients report negative physiological effects. A few value their appetite and weight gain, or even their decrease of sexual drive, but most patients do not. Neither do they appreciate the well-known extrapyramidal or anticholinergic side-effects. The overall impression is that the existing questionnaires ignore the large variety of subjective evaluations of similar effects by different patients.
The DAI-10 measures attitude (five items) as well as subjective response (five items) (Hogan et a., 1983) . The subjective response items are limited to a few general psychological and activation statements. It is evident that the DAI-10 is not only hybrid but also far from complete regarding the coverage of the spectrum of relevant experiences.
The DAI-30 (Hogan et al., 1983 ) covers a broader spectrum, but it lacks items on positively valued activation, decreased emotion and cognition effects. There are no items concerning sociability and physiology. Several subscales (health/illness, physician, control, prevention and harm) describe experiences that do not seem to be subjective responses to antipsychotic medication use. Therefore the DAI-30 is also incomplete.
The subscales of the SWN (Naber et al., 1994) agree to varying extents with our data. The subscale 'emotional regulation' is completely covered by our emotional set. The subscale 'self-control' describes psychotic experiences rather than medication effects. Some of the items are found in our cognitive set. The subscale 'mental functioning' is largely covered by our cognitive item set. The subscale 'social integration' is partly covered by our emotional and sociability item sets, but it also includes derealization experiences. The subscale 'physical functioning' agrees well with our activation set, but it also includes depersonalization experiences.
Compared with our domains, the SWN is also incomplete. For example, it lacks items which measure the positive valuation of a decrease of emotion (e.g. 'I am less anxious'), the negative valuation of an increase of activation (e.g. 'I feel more restless'), all of the physiological items (e.g. 'I have more of an appetite'), and most of the sociability items (e.g.
'I can follow a conversation better'). On the other hand, the SWN includes a range of psychopathological items that do not seem to belong in a scale like this. The SWN, as well as the SWN short form (Naber et al., 2001) , measures the quality of life rather than the response to antipsychotic medication described by Awad (1993) . The different versions of the SWN, the short form SWN, DAI-10 as well as DAI-30 do not take into account that there are several experiences that may be evaluated positively or negatively.
In conclusion, our 'bottom-up' study reveals that patients have a large variety of subjective experiences which they attribute to the use of antipsychotic medication. There is a place for a new instrument which covers this spectrum of positive and negative experiences in emotional, cognitive, sociability, activation and physiological domains, and which acknowledges the fact that the same effects may be positively or negatively experienced by different patients. Such an instrument would be a useful tool in the evaluation of antipsychotic drug effects, both for clinical and for research purposes. We are now obtaining psychometric data of a new self-report scale for measuring antipsychotic drug effects, which is based on the results of this exploratory study.
